Generation of Tau Aggregates and Clearance by Autophagy in an Inducible Cell Model of Tauopathy
- 18 February 2010
- journal article
- research article
- Published by S. Karger AG in Neurodegenerative Diseases
- Vol. 7 (1-3), 103-107
- https://doi.org/10.1159/000285516
Abstract
We have studied the mechanism of aggregation in an inducible cell model of Tau pathology. When the repeat domain of human Tau (TauRD) carrying the FTDP-17 mutation ΔK280 is expressed, the cells develop aggregates, as seen by thioflavin S fluorescence, electron microscopy, and sarkosyl extraction methods. By contrast, mutants of TauRD that are unable to generate β-structure do not aggregate. Enhanced aggregation leads to enhanced toxicity, visible by live cell microscopy and LDH release assay. The aggregation process is initiated by the sequential cleavage of TauRD which yields highly amyloidogenic fragments. This cleavage occurs only with proaggregant TauRD, and not with the nonaggregating mutants, indicating that β-structure makes TauRD vulnerable to both proteolytic degradation and aggregation. Aggregation is reversed by switching off the expression of TauRD, by inhibitor compounds, and by certain protease inhibitors. In all cases, the enhanced toxicity is rescued. The clearance of the aggregates involves autophagy, whereas proteasomal degradation plays only a minor role.Keywords
This publication has 13 references indexed in Scilit:
- Tau fragmentation, aggregation and clearance: the dual role of lysosomal processingHuman Molecular Genetics, 2009
- Autophagy and aging: keeping that old broom workingTrends in Genetics, 2008
- The Potential for β-Structure in the Repeat Domain of Tau Protein Determines Aggregation, Synaptic Decay, Neuronal Loss, and Coassembly with Endogenous Tau in Inducible Mouse Models of TauopathyJournal of Neuroscience, 2008
- The β-Propensity of Tau Determines Aggregation and Synaptic Loss in Inducible Mouse Models of TauopathyPublished by Elsevier BV ,2007
- Clinical and pathological features of an Alzheimer's disease patient with the MAPT ΔK280 mutationNeurobiology of Aging, 2007
- Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell modelProceedings of the National Academy of Sciences of the United States of America, 2007
- A Genomic Screen for Modifiers of Tauopathy Identifies Puromycin-Sensitive Aminopeptidase as an Inhibitor of Tau-Induced NeurodegenerationNeuron, 2006
- Rapamycin alleviates toxicity of different aggregate-prone proteinsHuman Molecular Genetics, 2005
- CHIP-Hsc70 Complex Ubiquitinates Phosphorylated Tau and Enhances Cell SurvivalPublished by Elsevier BV ,2004
- CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregationHuman Molecular Genetics, 2004